We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Caffeine May Slow Alzheimer's Disease and Other Dementias

By HospiMedica International staff writers
Posted on 01 Jun 2010
Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may have a protective effect against the cognitive decline seen in dementia and Alzheimer's disease (AD).

Researchers at the University of Lisbon (Portugal) and the University of Coimbra (Portugal) assembled a group of international experts to explore the effects of caffeine on the brain, and the possible therapeutic opportunities for caffeine in AD and other neurodegenerative diseases. More...
The collected studies shed new light on this topic and convey multiple perspectives on related issues such as the suggested molecular targets of caffeine, neurophysiological modifications and adaptations, and the potential mechanisms underlying the behavioral and neuroprotective actions of caffeine in distinct brain pathologies.

Among the specific subjects studied were the beneficial effects of caffeine in normalizing brain function and preventing it's degeneration; caffeine's neuroprotective profile and its ability to reduce amyloid-beta production; caffeine's role as a candidate disease-modifying agent for AD; the positive impact of caffeine on cognition and memory performance; the identification of adenosine A2A receptors as the main target for neuroprotection afforded by caffeine consumption; and the discussion of epidemiological studies, corroborated by meta-analysis, that suggest that caffeine may also be protective against Parkinson's disease. The collection of original studies was published as a special supplement to the May 2010 issue of the Journal of Alzheimer's Disease.

"Epidemiological studies first revealed an inverse association between the chronic consumption of caffeine and the incidence of Parkinson's disease,” wrote the supplement's guest editors, Alexandre de Mendonça, M.D., Ph.D., of the University of Lisbon and Rodrigo Cunha, Ph.D., of the University of Coimbra. "This was paralleled by animal studies of Parkinson's disease showing that caffeine prevented motor deficits as well as neurodegeneration.”

"Later a few epidemiological studies showed that the consumption of moderate amounts of caffeine was inversely associated with the cognitive decline associated with aging as well as the incidence of Alzheimer's disease,” they added. "Again, this was paralleled by animal studies showing that chronic caffeine administration prevented memory deterioration and neurodegeneration in animal models of aging and of Alzheimer's disease.”

Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated.

Related Links:

University of Lisbon
University of Coimbra



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.